Grove Bank & Trust’s Cidara Therapeutics CDTX Stock Holding History

Grove Bank & Trust’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-33	Closed	-$3.16K	–	860
2025 Q3	$3.16K	Buy	+33	New	+$2.11K	﹤0.01%	751

Other funds holding CDTX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Grove Bank & Trust's CDTX Position: Q4 2025 in Review

Grove Bank & Trust sold out of Cidara Therapeutics (CDTX) in Q4 2025, closing a stake of 33 shares — an estimated $3.16K sold.

Grove Bank & Trust first reported a position in CDTX in Q3 2025 and held it in 1 quarter. The position peaked at $3.16K in Q3 2025. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

Grove Bank & Trust reported no remaining Cidara Therapeutics position as of Q4 2025 after selling out during the quarter.
Grove Bank & Trust sold 33 Cidara Therapeutics shares in Q4 2025, an estimated $3.16K.
Grove Bank & Trust first reported a position in Cidara Therapeutics in Q3 2025 and held it in 1 quarter.
Grove Bank & Trust's Cidara Therapeutics position peaked at $3.16K in Q3 2025.
255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on Grove Bank & Trust's 13F filing for Q4 2025, filed 8 Jan 2026.